Ampersand Medical/AccuMed
This article was originally published in The Gray Sheet
Executive Summary
Cancer screening system developer Ampersand Medical announces $6 mil. stock-swap acquisition of diagnostic cytology and histology instrument maker AccuMed Feb. 7. Firms expect to close the deal during second quarter of 2001